Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anktiva in Long COVID
NCT07123727Phase 2Recruiting
- Sponsor
- ImmunityBio, Inc.
- Start
- Sep 2025
- Primary completion
- Mar 2027
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of nogapendekin alfa inbakicept in post-COVID-19 condition (PCC), sponsored by ImmunityBio, Inc.. Started Sep 2025; status: recruiting.
02
Drugs
nogapendekin alfa inbakicept
03
Conditions
post-COVID-19 condition (PCC)
Beyond the preview
Go deeper on NCT07123727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07123727.